Kalaris Therapeutics (NASDAQ:KLRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Kalaris Therapeutics (NASDAQ:KLRS) reported a quarterly EPS of ($0.64), surpassing analysts' expectations of ($0.66) by $0.02. The stock decreased by $0.21 to $4.86 with a trading volume of 39,043 shares. Institutional investors own 66.05% of the stock. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average price target of $11.50.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.02, Zacks reports.

Get Kalaris Therapeutics alerts:

Kalaris Therapeutics Stock Performance

Kalaris Therapeutics stock traded down $0.21 during trading on Wednesday, reaching $4.86. The stock had a trading volume of 39,043 shares, compared to its average volume of 128,651. The stock has a market capitalization of $90.88 million, a PE ratio of -1.20 and a beta of 0.42. The firm has a 50 day moving average of $5.04. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $15.63.

Institutional Trading of Kalaris Therapeutics

A hedge fund recently bought a new stake in Kalaris Therapeutics stock. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 24,234 shares of the company's stock, valued at approximately $65,000. XTX Topco Ltd owned about 0.13% of Kalaris Therapeutics as of its most recent filing with the SEC. 66.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on KLRS. Piper Sandler set a $3.00 target price on Kalaris Therapeutics and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Raymond James Financial started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a "strong-buy" rating for the company. Wall Street Zen lowered shares of Kalaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Citizens Jmp began coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They set a "market outperform" rating and a $20.00 target price for the company. Finally, Citigroup began coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They issued an "outperform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $11.50.

Read Our Latest Analysis on KLRS

Kalaris Therapeutics Company Profile

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Should You Invest $1,000 in Kalaris Therapeutics Right Now?

Before you consider Kalaris Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kalaris Therapeutics wasn't on the list.

While Kalaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here